Final Say On Prescriptions, Potency, and More!
No images? Click here
Declaring the Result of Drug Test
Who Has the Final Say on Prescriptions
Medical Review Officers (MROs) are licensed physicians who play an imperative role in authenticating if there is a legitimate medical/legal explanation for a controlled substance to be present in an employee’s specimen, (i.e., a valid prescription). Even if the “non-negative” result is for a Schedule I drug (which are considered to have no medical value), the MRO will still attempt to interview the employee to determine if there is a valid reason for the presence of the substance.
Long acknowledged for their defensibility and employee privacy protections, federally mandated drug tests (e.g., under the Department of Transportation regulations) require the involvement of an MRO. These federal testing protocols are considered best practice for drug testing even for non-DOT employees and include these steps:
Adult Use Marijuana Legalization Update:
No movement from Statehouse – Potency levels remain a concern
When last we reported, both Ohio’s Senate and House had stalled in their work on legislative proposals and revisions in an effort to navigate the complexities of enacting and administrating Ohio’s Adult Use Marijuana law which Ohio voters approved on November 7, 2023, and which went into effect on December 7, 2023.
Let's review potency concerns and what this means for the employer.
COMING SOON!
We're excited to announce that Working Partners® will be hosting an insightful webinar on the latest updates regarding marijuana in Ohio and its implications for the workplace. Stay tuned for more information and details regarding this webinar by keeping an eye on your emails, Facebook, and LinkedIn for more details!
HOW TO PROVIDE COMMENT FOR THE DEA’S NOTICE OF PROPOSED RULEMAKING (NPRM) REGARDING THE RESCHEDULING OF MARIJUANA
Make your voice heard! You can have an impact on the U.S. Drug Enforcement Administration’s proposal to reschedule marijuana from a Schedule I drug to a Schedule III drug under the Controlled Substances Act by providing comment to the NPRM.
